ans-6637
Small moleculeexperimental
Clinical trial activity
5 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2017 (NCT03203499)
Timeline
Indications
Mechanism of action
- Aldehyde dehydrogenaseINHIBITOR
ALDH2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ans-6637
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04311294 | Phase 2 | Apr 30, 2020 | Amygdala Neurosciences, Inc., National Institute on Alcohol Abuse and Alcoholism (NIAAA), University of California, Los Angeles |
| NCT04169360 | Phase 2 | Jan 31, 2020 | University of Maryland |
| NCT03970109 | Phase 2 | Jul 1, 2019 | National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
| NCT03831971 | Phase 1 | Mar 1, 2019 | National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) |
| NCT03203499 | Phase 1 | Jul 1, 2017 | Amygdala Neurosciences, Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Amygdala Neurosciences, Inc. | For profit | 2 | 1 | 2 | 2017 |
| National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Government | 2 | 1 | 1 | 2019 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 0 | 1 | 2019 |
| National Institutes of Health (NIH) | Government | 1 | 1 | 1 | 2019 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of Maryland | Academic/Hospital | 1 | 1 | 1 | 2020 |
6 organizations
Page 1 / 1